Open access
From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management
Abstract
The publication of the joint EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy represents a watershed moment in hepatology [...]